You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

COVID-19 in Pediatrics: Selecting Optimal Treatment

  • Authors: Cameron R. Wolfe, MBBS(Hons), MPH, FIDSA; Monique Soileau-Burke, MD, IBCLC, FAAP; Hai P. Tran, PharmD, BCPS
  • CME / ABIM MOC / CE Released: 3/9/2022
  • Valid for credit through: 3/9/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for pediatricians, infectious disease/HIV specialists, emergency medicine physicians, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other practice providers in the outpatient setting involved in the management of pediatric patients with COVID-19.

The goal of this activity is for clinicians to identify patients at high risk for severe COVID-19 and identify appropriate treatment to improve outcomes.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Identifying pediatric patients who are at risk for severe COVID-19
    • Discussing treatment option expectations with parents/caregivers
  • Demonstrate greater confidence in their ability to
    • Recommend available therapy for eligible pediatric patients
    • Coordinate with the interprofessional team to implement outpatient treatment for appropriate pediatric patients


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Cameron R. Wolfe, MBBS(Hons), MPH, FIDSA

    Associate Professor of Medicine 
    Division of Infectious Diseases 
    Duke University School of Medicine 
    Durham, North Carolina

    Disclosures

    Consultant or advisor for: Adagio; Enzychem; Regeneron
    Research funding from: Ansun; Gilead
    Other: Drug Safety Monitoring Board: Atea; Biogen; Janssen

  • Monique Soileau-Burke, MD, IBCLC, FAAP

    Vice President
    Maryland American Academy of Pediatrics 
    The Pediatric Center, LLC
    Columbia, Maryland 

    Disclosures

    No relevant financial relationships

  • Hai P. Tran, PharmD, BCPS

    Pharmacy Associate Director 
    Cedars-Sinai ​Medical Center
    Los Angeles, California

    Disclosures

    Owns stock (publicly traded) in: AstraZeneca; Capricor; Moderna

Editors

  • Maria B. Uravich, BSc, ELS

    Medical Education Director,
    Medscape, LLC   

    Disclosures

    Disclosure: Maria B. Uravich, BSc, ELS, has no relevant financial relationships.

  • Jennifer Gregg, PhD

    Medical Education Director,
    WebMD Global, LLC 

    Disclosures

    Disclosure: Jennifer Gregg, PhD, has no relevant financial relationships. 

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) ( 0.050 CEUs) (Universal Activity Number: UAN JA0007105-0000-22-069-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

COVID-19 in Pediatrics: Selecting Optimal Treatment

Authors: Cameron R. Wolfe, MBBS(Hons), MPH, FIDSA; Monique Soileau-Burke, MD, IBCLC, FAAP; Hai P. Tran, PharmD, BCPSFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/9/2022

Valid for credit through: 3/9/2023

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to COVID-19 vaccines and/or therapeutics are provided in this activity in an effort to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer

 

 

Post-Assessment Survey

What did you learn from this activity? Please proceed to a brief survey.